Free Trial

Kalaris Therapeutics (KLRS) News Today

Kalaris Therapeutics logo
$2.40 -0.17 (-6.61%)
As of 04:00 PM Eastern

KLRS Latest News

Allovir (NASDAQ:KLRS) Stock Rating Lowered by Wall Street Zen
Kalaris Therapeutics Inc. stock logo
Allovir (NASDAQ:KLRS) Cut to Sell at Wall Street Zen
Wall Street Zen downgraded Allovir from a "hold" rating to a "sell" rating in a report on Monday.
Kalaris Therapeutics Inc. stock logo
Allovir (NASDAQ:KLRS) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen upgraded shares of Allovir from a "sell" rating to a "hold" rating in a research note on Sunday.
Get Kalaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter.

KLRS Media Mentions By Week

KLRS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

KLRS
News Sentiment

0.63

0.68

Average
Medical
News Sentiment

KLRS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

KLRS Articles
This Week

1

3

KLRS Articles
Average Week

Get Kalaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:KLRS) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners